Tonic B cell activation by Radioprotective105/MD-1 promotes disease progression in MRL/lpr mice

International Immunology

Volumn 20, Issue 7, 2008, Pages 881-891

  Kobayashi, Toshihiko ^a,b   Takahashi, Koichiro ^a   Nagai, Yoshinori ^a,e   Shibata, Takuma ^a   Otani, Masako ^c   Izui, Shozo ^c   Akira, Shizuo ^d   Gotoh, Yoshiyuki ^a   Kiyono, Hiroshi ^a   Miyake, Kensuke ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d OSAKA UNIVERSITY   (Japan)

^e UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Autoimmunity; B cells; Innate immunity

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; AUTOANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; METRONIDAZOLE; NEOMYCIN; NITROGEN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UREA; VANCOMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTERITIS; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GERM LINE; GLOMERULONEPHRITIS; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; INCIDENCE; INFECTION RESISTANCE; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHADENOPATHY; MICROFLORA; MOUSE; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; SPLENOMEGALY; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTIGENS, CD; AUTOANTIBODIES; B-LYMPHOCYTES; DISEASE PROGRESSION; FEMALE; GLOMERULONEPHRITIS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, INBRED MRL LPR; MICE, KNOCKOUT; SIGNAL TRANSDUCTION; SPECIFIC PATHOGEN-FREE ORGANISMS; TOLL-LIKE RECEPTORS;

EID: 45749098222     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxn049     Document Type: Article

References (46)

1. Theofilopoulos, A. N. and Dixon, F. J. 1985. Murine models of systemic lupus erythematosus. Adv. Immunol. 37:269.
2. Andrews, B. S., Eisenberg, R. A., Theofilopoulos, A. N. et al. 1978. Spontaneous murine lupus-like syndromes. Clinical and immuno-pathological manifestations in several strains. J. Exp. Med. 148:1198.
3. Marshak-Rothstein, A. and Rifkin, I. R. 2007. Immunologically active autoantigens: The role of toll-like receptors in the development of chronic inflammatory disease. Annu. Rev. Immunol. 25:419.
4. Lau, C. M., Broughton, C., Tabor, A. S. et al. 2005. RNA-associated autoantigens activate B cells-by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 202:1171.
5. Christensen, S. R., Shupe, J., Nickerson, K., Kashgarian, M., Flavell, R. A. and Shlomchik, M. J. 2006. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25:417.
6. Schaefer, L., Babelova, A., Kiss, E. et al. 2005. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J. Clin. Invest. 115:2223.
7. Paterson, H. M., Murphy, T. J., Purcell, E. J. et al. 2003, Injury primes the innate immune system for enhanced Toll-like receptor reactivity. J. Immunol. 171:1473.
8. Wu, H., Chen, G., Wyburn, K. R. et al. 2007. TLR4 activation mediates kidney ischemia/reperfusion injury. J. Clin. Invest. 117:2847.
9. Apetoh, L., Ghiringhelli, F., Tesniere, A. et al. 2007. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13:1050.
10. Vogl, T., Tenbrock, K., Ludwig, S. et al. 2007. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 13:1042.
11. Miyake, K. 2007. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin. Immunol. 19:3.
12. Miyake, K., Shimazu, R., Kondo, J. et al. 1998. Mouse MD-1, a molecule that is physically associated with RP105 and positively regulates its expression. J. Immunol. 161:1348.
13. Miyake, K., Yamashita, Y., Ogata, M., Sudo, T. and Kimoto, M. 1995. RP105, a novel B cell surface molecule implicated in B cell activation, is a member of the leucine-rich repeat protein family. J. Immunol. 154:3333.
14. Ogata, H., Su, I., Miyake, K. et al. 2000. The toll-like receptor protein RP105 regulates lipopolysaccharide signaling in B cells. J. Exp. Med. 192:23.
15. Miyake, K. 2003. Innate recognition of lipopolysaccharide by CD14 and toll-like receptor 4-MD-2: Unique roles for MD-2. Int. Immunopharmacol. 3:119.
16. Nagai, Y., Kobayashi, T., Motoi, Y. et al. 2005. The radioprotective 105/MD-1 complex links TLR2 and TLR4/MD-2 in antibody response to microbial membranes. J. Immunol. 174:7043.
17. Divanovic, S., Trompette, A., Atabani, S. F. et al. 2005. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol. 6:571.
18. Nagai, Y., Shimazu, R., Ogata, H. et al. 2002. Requirement for MD-1 in cell surface expression of RP105/CD180 and B-cell responsiveness to lipopolysaccharide. Blood 99:1699.
19. Luzuy, S., Merino, J., Engers, H., Izui, S. and Lambert, P. H. 1986. Autoimmunity after induction of neonatal tolerance to alloantigens: Role of B cell chimerism and F1 donor B cell activation. J. Immunol. 136:4420.
20. Vyse, T J., Rozzo, S. J., Drake, C. G., Izui, S, and Kotzin, B. L. 1997. Control of multiple autoantibodies linked with a lupus nephritis susceptibility locus in New Zealand black mice. J. Immunol. 158:5566.
21. Kuroki, A., Moll, T, Lopez-Hoyos, M. et al. 2004. Enforced Bcl-2 expression in B lymphocytes induces rheumatoid factor and anti-DNA production, but the Yaa mutation promotes only anti-DNA production. Eur. J. Immunol. 34:1077.
22. Yazawa, N., Fujimoto, M., Sato, S. et al. 2003. CD19 regulates innate immunity by the toll-like receptor RP105 signaling in B lymphocytes. Blood 102:1374.
23. Pasare, C. and Medzhitov, R. 2005. Control of B-cell responses by Toll-like receptors. Nature 438:364.
24. Yamamoto, M., Sato, S., Hemmi, H. et al. 2002. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 420:324.
25. Schnare, M., Barton, G. M., Holt, A. C., Takeda, K., Akira, S. and Medzhitov, R. 2001. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2:947.
26. Honjo, T., Nagaoka, H., Shinkura, R. and Muramatsu, M. 2005. AID to overcome the limitations of genomic information. Nat. Immunol. 6:655.
27. Muramatsu, M., Kinoshita, K., Fagarasan, S., Yamada, S., Shinkai, Y. and Honjo, T. 2000. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102:553.
28. Macpherson, A. J., Gatto, D., Sainsbury, E., Harriman, G. R., Hengartner, H. and Zinkernagel, R. M. 2000. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science 288:2222.
29. Maldonado, M. A., Kakkanaiah, V., MacDonald, G. C. et al. 1999. The role of environmental antigens in the spontaneous development of autoimmunity in MRL-Ipr mice. J. Immunol. 162:6322.
30. Alexander, E. L., Moyer, C., Travlos, G. S., Roths, J. B. and Murphy, E. D. 1985. Two histopathologic types of inflammatory vascular disease in MRL/Mp autoimmune mice. Model for human vasculitis in connective tissue disease. Arthritis Rheum. 28:1146.
31. Cohen, P. L. and Eisenberg, R. A. 1991. Lpr and gld: Single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev Immunol. 9:243.
32. Kikuchi, S., Pastore, Y., Fossati-Jimack, L. et al. 2002. A transgenic mouse model of autoimmune glomerulonephritis and necrotizing arteritis associated with cryoglobulinemia. J. Immunol. 169:4644.
33. Gorczynski, R. M., Kai, Y. and Miyake, K. 2006. MD1 expression regulates development of regulatory T cells. J. Immunol. 177:1078.
34. Takeuchi, O., Hoshino, K., Kawai, T. et al. 1999. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11:443.
35. Hoshino, K., Takeuchi, O., Kawai, T. et al. 1999. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TILR4 as the Lps gene product. J. Immunol. 162:3749.
36. Chan, O. and Shlomchik, M. J. 1998. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-Ipr/ Ipr mice. J. Immunol. 160:51.
37. Shlomchik, M. J., Madaio, M. P., Ni, D., Trounstein, M. and Huszar, D. 1994. The role of B cells in Ipr/Ipr-induced autoimmunity. J. Exp. Med. 180:1295.
38. Chan, O. T., Hannum, L. G., Haberman, A. M., Madaio, M. P. and Shlomchik, M. J. 1999. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 189:1639.
39. Anolik, J. H., Barnard, J., Cappione, A. et al. 2004. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 50:3580.
40. Hu, C. Y., Rodriguez-Pinto, D., Du, W. et al. 2007. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 117:3857.
41. Clynes, R., Dumitru, C. and Ravetch, J. V. 1998. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 279:1052.
42. Bergtold, A., Gavhane, A., D'Agati, V., Madaio, M. and Clynes, R. 2006. FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis. J. Immunol. 177:7287.
43. Matsumoto, K., Watanabe, N., Akikusa, B. et al. 2003. Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRL/Ipr mice. Arthritis Rheum. 48:486.
44. Santiago-Raber, M. L., Baccala, R., Haraldsson, K. M. et al. 2003. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197:777.
45. Hron, J. D. and Peng, S. L. 2004. Type I IFN protects against murine lupus. J. Immunol. 173:2134.
46. Ehlers, M., Fukuyama, H., McGaha, T L., Aderem, A. and Ravetch, J. V. 2006. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J. Exp. Med. 203:553.